CapsoVision, Inc 8-K

What Happened
CapsoVision announced on July 1–2, 2026 that Dr. David S. Shields was appointed as a Class I director and member of the Compensation Committee, effective July 1, 2026, replacing Dr. Joanne Imperial, who resigned from the Board the same day. The company filed a press release on July 2, 2026 to announce the changes. The Board determined Dr. Shields is an independent director and he will participate in the company’s standard non‑employee director compensation and has signed the company’s standard director indemnification agreement.

Key Details

• Dr. David S. Shields (age 75) is a board‑certified gastroenterologist with decades of clinical and academic experience; he will also provide clinical consulting services under a consulting agreement at US$600/hour for up to 3 hours per work week.
• Dr. Joanne Imperial stepped down from the Board effective July 1, 2026; her resignation was not due to any disagreement with management or the Board.
• Dr. Imperial will continue as an independent consultant under an amended and restated consulting agreement (dated July 2, 2026) at US$600/hour for up to 5 hours per work week and received an option to buy 10,000 shares of common stock (exercise price = fair market value as of July 2, 2026). Vesting: 25% after one year (July 2, 2027) and then 1/48 of the grant vests each month thereafter, subject to continued consultancy.
• The company furnished a press release as Exhibit 99.1 in the 8‑K.

Why It Matters
This filing updates investors on a change in board composition and ongoing access to clinical expertise: Dr. Shields’ appointment maintains a physician perspective on the Board and on the Compensation Committee, while Dr. Imperial remains engaged as a paid consultant. Financially, the disclosed items are limited to hourly consulting fees and a 10,000‑share option grant to Dr. Imperial; there is no indication in the filing of disagreements with management or broader governance concerns.